LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

评估呼吸道病毒感染的两阶段算法

By LabMedica International staff writers
Posted on 01 May 2018
图片:Sofia甲流乙流FIA检验试剂盒(图片蒙Quidel公司惠赐)。
图片:Sofia甲流乙流FIA检验试剂盒(图片蒙Quidel公司惠赐)。
新型按需多重呼吸道病毒分子诊断产品虽然昂贵,且某些平台不能同时处理多份样本,但是性能卓越。
 
商用组合型分子诊断产品可快速检测阳性血液培养瓶、呼吸道样本、大便和脑脊液中的病原体,最近的发展引起临床微生物检验与临床规程的转变。
 
美国马萨诸塞州波士顿市塔夫斯医疗中心(www.tuftsmedicalcenter.org)的科学家开展了一项回顾性研究,回顾患者的呼吸道病毒检验结果,之前还对这些患者应用了一套两阶段检验算法,先用美国加利福尼亚州圣迭戈市Quidel公司(www.quidel.com)的Sofia免疫测定产品筛查,再用美国北卡罗莱纳州杜勒姆市生物梅里埃股份有限公司(www.biomerieux-usa.com)的Biofire膜阵列,并与只用膜阵列的时期比较。具体而言,在冬季流感季用两阶段方法处理了1,814份样本。然后与夏季单用膜阵列处理1,162份样本的方案做了比较。
 
科研小组用Quidel公司的Sofia流感免疫测定通过两阶段方法成功诊断了282例流感。然后他们用膜阵列组合试剂检验了流感免疫测定结果呈阴性的全部鼻咽样本,又发现了单用免疫测定所漏检的163例流感病例。两阶段方法还包括用呼吸道合胞病毒(RSV)免疫测定产品检验五岁以下的儿童以及内科医生送检的成人,共363名患者。约28%的样本Sofia检测RSV的结果为阴性,但是膜阵列检测RSV的结果为阳性,而且膜阵列又发现了未接受免疫测定的患者中的71例RSV病例。虽然冬季检验的样本更多,但是在90分钟内得到诊断的患者人数也多得多,大概节省了36,000美元。
 
该研究的论文发表于2018年3月12日的《诊断微生物学与传染病》(Diagnostic Microbiology and Infectious Disease)杂志。论文合著者之一、传染病医师Brad J. Gardiner说:“如果你做出的诊断改变了病人的预后,钱就花得值,但如果你正在诊断感染鼻病毒的患者且不会产生差别,则钱最好花在别处。”
 
Related Links:

塔夫斯医疗中心>>> www.tuftsmedicalcenter.org

Quidel >>> www.quidel.com

生物梅里埃股份有限公司>>> www.biomerieux-usa.com


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
8-Channel Pipette
SAPPHIRE 20–300 µL

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more